How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic

Early‑stage biotechs are rethinking how they choose bioanalysis partners, and the shift traces directly back to what the pandemic made impossible to ignore. Large CROs, built to serve high‑volume pharma programs, struggled to provide predictability when capacity tightened. Studies that were nominally prioritized sat in queues, communication slowed, and turnaround commitments slipped — outcomes that created disproportionate risk for companies whose financing and study decisions hinge on timely data.

This has pushed Series A and B teams to reassess what they actually need: reliable speed, direct scientific access, flexibility when study designs evolve, and transparent pricing that removes budget ambiguity. Smaller, operationally agile bioanalysis labs increasingly fit this profile. They offer the ability to engage directly with the scientists running the assays, adapt quickly to changing sample sets, and provide itemized pricing that aligns with lean operational budgets.

Regulatory credibility remains essential, but experience has shown that high‑quality GLP work does not require a large CRO—only a well‑designed facility, rigorous QA processes, and a culture built around precision. As a result, many emerging biotechs are adopting a more deliberate, segmented selection model that pairs GLP rigor with preclinical speed, often opting for specialized partners built for programs at their scale.